Q: WHAT IS THE COLLABORATION BETWEEN BETH ISRAEL DEACONESS MEDICAL CENTER AND DEERFIELD MANAGEMENT COMPANY?
A: Beth Israel Deaconess Medical Center (BIDMC) is collaborating with Deerfield Management Company, an investment firm dedicated to advancing healthcare, to accelerate the translation of research emerging from BIDMC. The collaboration, Brookline Avenue Innovations, LLC, is a private company wholly owned by affiliates of Deerfield Management. Its objective is to fund projects that discover novel therapeutics that have the potential to cure life-altering diseases. This collaboration will rely on the novel insights BIDMC researchers and clinicians have and will leverage Deerfield's expertise in accelerating state-of-the-art drug development. Deerfield has committed up to $130 million and additional scientific and operational support.
Q: WHO IS ELIGIBLE TO APPLY?
A: Principal Investigators whose principal employer is BIDMC or who have a faculty appointment at BIDMC and are therefore subject to BIDMC’s institutional policies are eligible to apply.
Q: HOW CAN I APPLY?
A: Interested faculty should reach out to Cindy Wong (BIDMC - Technology Ventures Office) at cwong2@bidmc.harvard.edu for more information on proposal submission.
Q: DOES BROOKLINE AVENUE INNOVATIONS HAVE A THERAPEUTIC AREA OF INTEREST?
A: No. Brookline Avenue Innovations welcomes applications from all therapeutic areas and modalities.